Mihály Tapolyai

Dr. Mihály Tapolyai

Division of Nephrology, VA Medical Center, Memphis, TN, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Journal of Clinical & Translational Endocrinology
Verified
Journal Article
Open access
ÁPÁkos Pethő
Ákos Pethő
MTMihály Tapolyai
Mihály Tapolyai
ÉCÉva Csongrádi
Éva Csongrádi
POPetronella Orosz
Petronella Orosz
Chronic kidney disease (CKD) is a progressive and incurable condition that imposes a significant burden on an aging society. Although the exact prevalence of this disease is unknown, it is estimated to affect at least 800 million people worldwide. Patients with diabetes or hypertension are at a higher risk of developing chronic kidney damage. As the kidneys play a crucial role in vital physiological processes, damage to these organs can disrupt the balance of water and electrolytes, regulation of blood pressure, elimination of toxins, and metabolism of vitamin D. Early diagnosis is paramount to prevent potential complications. Treatment options such as dietary modifications and medications can help slow disease progression. In our narrative review, we have summarized the available therapeutic options to slow the progression of chronic kidney disease. Many new drug treatments have recently become available, offering a beacon of hope and optimism in CKD management. Nonetheless, disease prevention remains the most critical step in disease management. Given the significant impact of CKD on public health, there is a pressing need for further research. With the development of new technologies and advancements in medical knowledge, we hope to find more effective diagnostic tools and treatments for CKD patients.

30 January 2013 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
MTMihály Tapolyai
Mihály Tapolyai
MFMária Faludi
Mária Faludi
VRVirág Réti
Virág Réti
ZLZsolt Lengvárszky
Zsolt Lengvárszky
TSTibor Szarvas
Tibor Szarvas
KBKlára Berta
Klára Berta

1 November 2011 in ASAIO Journal
Verified
Journal Article
Closed access
MTMihály Tapolyai
Mihály Tapolyai
MFMária Faludi
Mária Faludi
VRVirág Réti
Virág Réti
ZLZsolt Lengvárszky
Zsolt Lengvárszky
TSTibor Szarvas
Tibor Szarvas
KBKlára Berta
Klára Berta
Overhydration (OH) is both a major etiology of hypertension in hemodialysis patients and a serious risk factor for mortality. We investigated the association of multiple variables and OH. This is a cross-sectional study of prevalent hemodialysis patients examining the predialysis hydrational status with a portable bioimpedance apparatus to measure the degree of hydration. We completed our study in 79 patients. Patients were overhydrated by 2.6 ± 2.4 L. The mean medication count was 2.4 ± 1.5, and 50.7% had diuretics. We found a significant correlation between OH and systolic blood pressure (r = 0.39; p = 0.0006), each liter of OH generating 3.6 mm Hg. We also found a positive correlation between the use of diuretics and OH (p = 0.003, two-tailed Student's t test) but no correlation between OH and body weight (r < 0.0001; p = 0.99), body mass index (r = −0.17), age (r = 0.089), and vintage (r = 0.05). For every 10% increase in body fat, OH decreased by 1.2 L; residual urine output gave no protection from OH (r = 0.077) and did not correlate with blood pressure (r = 0.01). Overhydration is strongly associated with the use of antihypertensive medications and the use of diuretics in this dialysis population. Obesity seems to afford some protection from OH.

19 January 2014 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
MTMihály Tapolyai
Mihály Tapolyai
MFMária Faludi
Mária Faludi
TFTibor Fülöp
Tibor Fülöp
NDNeville R. Dossabhoy
Neville R. Dossabhoy
ASAnita Szombathelyi
Anita Szombathelyi
KBKlára Berta
Klára Berta

17 June 2003 in BMC Nephrology
Verified
Journal Article
Open access
MTMihály Tapolyai
Mihály Tapolyai
SKSatoshi Kadomatsu
Satoshi Kadomatsu
MPManuel Perera-Chong
Manuel Perera-Chong
As EPO treatment of chronic anemia of advanced renal disease is now the standard of care we examined if such treatment may slow the progression of renal function decline. Data of 18 pre-ESRD patients were analyzed retrospectively 12 months prior and prospectively 12 months after the initiation of EPO. Mean creatinine was 5.0 ± 1.8 mg/dL (Mean ± SEM) when starting EPO at a weekly dose of 5000 ± 500 units once the hematocrit was below 30 %. EPO dose was titrated monthly for a hematocrit between 33.0% and 37.0%. Metabolic complications and hypertension were controlled. At month_0 the average blood pressure was 148/76 ± 5/4 mmHg and at month_12 it was 145/73 ± 6/3 mmHg (p = 0.75 by 2 tailed paired Student's t test). 12/18 patients were on an ACE-i or ARB before month_0 and 14/18 were on it after (p = 0.71 by Fisher's 2 tailed exact test). The average hematocrit rose from 26.9% ± 0.6 to 33.1 % ± 0.1. When linear regression analysis was applied to pre- and post-EPO 1/creatinine data the mean rate of decline was -0.0140 ± 0.0119 (mean ± SD) and -0.0017 ± 0.0090 (non-parametric Wilcoxon matched pairs signed rank sum test: Z value: -2.91; P = 0.004) respectively. 5/18 patients did not require dialysis 12 months after starting EPO (month_0). Treatment of the anemia of chronic renal failure with erythropoietin, when instituted together with vigorous metabolic control may slow the rate of renal function decline.

9 February 2021 in ASAIO Journal
Verified
Journal Article
Closed access
SSSohail Abdul Salim
Sohail Abdul Salim
AMAhmed Taher Masoud
Ahmed Taher Masoud
CTCharat Thongprayoon
Charat Thongprayoon
Wisit CheungpasitpornWisit Cheungpasitporn
Wisit Cheungpasitporn
KSKarim M. Soliman
Karim M. Soliman
Tibor FülöpTibor Fülöp
Tibor Fülöp
Catheter-related bloodstream infection (CRBSI) with hemodialysis catheters are associated with increased mortality, morbidity and pose significant financial burden on healthcare. Antibiotic and antimicrobial locking solutions are effective in reducing risk of CRBSI. From inception to April 2020, we looked for relevant clinical controlled trials throughout the following databases: EBSCO, PubMed, Cochrane CENTRAL, MEDLINE, EMBASE, clinicaltrial.gov, and Google Scholar performing a metanalysis comparing antibiotic and antimicrobial lock solutions to heparin. Twenty-six studies with 4,967 patients reported the incidence of catheter-related bacteremia (CRB). The overall pooled risk ratio (RR) showed that the intervention group was associated with a significantly lower incidence of CRB by 30% compared with heparin (RR = 0.30, 95% confidence interval [CI] [0.25, 0.36], p < 0.001). Subgroup analysis showed that administration of antibiotic regimens led to a decreased risk of CRB episodes by 28% compared with the heparin group (RR = 0.28, 95% CI [0.21, 0.37], p < 0.0001). Antimicrobial solutions was associated with reduced risk of CRB by 32% compared with patients of the control group (RR = 0.32, 95% CI [0.25, 0.41], p < 0.0001). A test of subgroup differences was revealed no significant favoring of any of the two interventions. Both antibiotic and antimicrobial solutions are effective in reducing CRBSI.